Earnings summaries and quarterly performance for Alto Neuroscience.
Executive leadership at Alto Neuroscience.
Board of directors at Alto Neuroscience.
Research analysts covering Alto Neuroscience.
Recent press releases and 8-K filings for ANRO.
Alto Neuroscience Outlines Key Pipeline Milestones and Biomarker Strategy
ANRO
New Projects/Investments
Guidance Update
M&A
- Alto Neuroscience is advancing four psychiatric drug candidates in Phase 2, all with expected readouts within the next two years, leveraging a biomarker-driven precision medicine approach.
- Key upcoming readouts include Alto 101 for cognition in schizophrenia in Q1 2026 and Alto 300 for adjunctive depression treatment in mid-2026.
- The Alto 207 program for treatment-resistant depression is set to launch Phase 2B in H1 2026 and Phase 3 by early 2027, with Phase 3 data anticipated in 2028 and potential market entry by 2029.
- Following an interim analysis, the Alto 300 Phase 2B study was slightly upsized, and the company has implemented rigorous new trial requirements to enhance execution quality across all programs.
Nov 17, 2025, 3:30 PM
Alto Neuroscience Details Upcoming Clinical Milestones
ANRO
New Projects/Investments
Guidance Update
- Alto Neuroscience, a psychiatric drug developer, has four different drugs in Phase 2 programs with readouts expected within the next two years.
- The next readout for Alto 101 (cognition in schizophrenia) is anticipated in Q1 2026.
- The Alto 207 program for treatment-resistant depression is on track to launch its Phase 2B in H1 2026, with a Phase 3 start guided for early 2027 and potential market entry by 2029, following accelerated timelines due to FDA discussions.
- Readouts for Alto 300 (adjunctive treatment in depression) are expected in mid-2026, and for Alto 100 (bipolar depression) in H2 2026.
- The company emphasizes a biomarker-driven approach to identify specific patient subpopulations for its drug candidates.
Nov 17, 2025, 3:30 PM
Alto Neuroscience Updates Clinical Pipeline and Funding
ANRO
New Projects/Investments
Guidance Update
- Alto Neuroscience, a psychiatric drug developer, is progressing multiple Phase 2 programs, with key readouts expected for Alto 101 in Q1 2026, Alto 300 in mid-2026, and Alto 100 in second half 2026.
- The Alto 207 program for treatment-resistant depression is launching its Phase 2B in the first half of 2026 and accelerating its Phase 3 launch to early 2027, following a $50 million PIPE led by Perceptive.
- The company maintains a cash runway into 2028, which is projected to fund all current development activities through these milestones.
Nov 12, 2025, 3:00 PM
Alto Neuroscience Provides Pipeline Updates and Financial Outlook
ANRO
New Projects/Investments
Guidance Update
- Alto Neuroscience is a psychiatric drug developer with all programs currently in Phase 2, primarily late Phase 2, focusing on a biology-forward precision approach.
- Key pipeline readouts include Alto 101 (cognitive impairment in schizophrenia) in Q1 2026, Alto 300 (adjunctive depression) in mid-2026, and Alto 100 (bipolar depression) in H2 2026.
- The Alto 207 program (treatment-resistant depression) is accelerating, with a Phase 2B launch in H1 2026 and a Phase 3 launch by early 2027, supported by a recent $50 million PIPE.
- The company's cash runway extends into 2028, covering all current activities and planned readouts.
Nov 12, 2025, 3:00 PM
Alto Neuroscience Provides Pipeline Update and Financial Outlook
ANRO
New Projects/Investments
Guidance Update
- Alto Neuroscience is developing psychiatric drugs using a precision medicine approach, with all programs currently in Phase 2, including late-stage trials.
- Key upcoming readouts include Alto 101 in Q1 2026, Alto 300 in mid-2026, and Alto 100 in the second half of 2026.
- The company plans to launch a Phase 2B trial for Alto 207 in the first half of 2026 and a Phase 3 trial by early 2027, with this acceleration supported by a recent $50 million PIPE investment.
- Alto Neuroscience's cash runway extends into 2028, covering all planned activities through these readouts.
Nov 12, 2025, 3:00 PM
Alto Neuroscience Reports Q3 2025 Financial Results and Pipeline Progress
ANRO
Earnings
Guidance Update
New Projects/Investments
- Alto Neuroscience secured $50 million in private placement financing (PIPE) in October 2025, bringing its cash balance to $184.2 million as of October 31, 2025, which is expected to fund planned operations into 2028.
- The company announced a successful FDA meeting for ALTO-207 in treatment-resistant depression, with a Phase 2b trial on track to initiate in the first half of 2026 and a Phase 3 trial by early 2027.
- Key clinical trial data readouts are anticipated, including ALTO-101 in cognitive impairment in schizophrenia (CIAS) in 1Q 2026, ALTO-300 in major depressive disorder (MDD) in mid-2026, and ALTO-100 in bipolar depression (BPD) in the second half of 2026.
- For the third quarter ended September 30, 2025, Alto Neuroscience reported a net loss of $14.2 million, compared to $16.8 million for the same period in 2024.
Nov 12, 2025, 1:02 PM
Alto Neuroscience Announces $50 Million Private Placement Financing
ANRO
Equity Issuance
New Projects/Investments
- Alto Neuroscience, Inc. (ANRO) announced a $50 million private placement financing led by Perceptive Advisors, with the closing expected on October 21, 2025.
- The financing includes the sale of 3,832,263 shares of common stock at $5.914 per share and pre-funded warrants to purchase up to 4,622,251 shares at $5.9139 per pre-funded warrant.
- Proceeds from the financing will be used to accelerate the development of ALTO-207 in Treatment Resistant Depression (TRD).
- This acceleration includes plans to initiate a Phase 2b study by mid-2026 and a Phase 3 study by early 2027.
- Alto maintains cash guidance into 2028, now incorporating these additional development activities for ALTO-207.
Oct 20, 2025, 8:01 PM
Alto Neuroscience Faces Class Action Lawsuit Over ALTO-100 Trial Results
ANRO
Legal Proceedings
Profit Warning
- A class action lawsuit has been filed against Alto Neuroscience, Inc. and certain officers, covering securities purchased between February 2, 2024, and October 22, 2024.
- The lawsuit alleges that the company made materially false and misleading statements regarding the effectiveness of its drug ALTO-100 in treating Major Depressive Disorder (MDD).
- This follows Alto's announcement on October 22, 2024, that ALTO-100 did not meet its primary endpoint in a Phase 2b clinical trial for MDD.
- Following this news, Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 on October 23, 2024.
- Investors who purchased Alto securities during the Class Period have until September 19, 2025, to ask the Court to appoint them as Lead Plaintiff.
Sep 18, 2025, 2:00 PM
Alto Neuroscience Discusses Biomarker Platform and Upcoming Clinical Milestones
ANRO
New Projects/Investments
M&A
- Alto Neuroscience employs a biomarker-driven platform utilizing tools like EEG and cognitive tests to select patients and de-risk drug development, an approach that aligns with FDA enrichment guidelines.
- The company provided updates on its late-stage pipeline, including ALTO-101 (cognitive impairment in schizophrenia) with topline data anticipated in the second half of next year, and ALTO-207 (treatment-resistant depression), acquired from Chase Therapeutics, which will begin its Phase IIB trial in the first half of next year. ALTO-207 previously demonstrated strong efficacy with Cohen's D values of 0.9 to 1.1 in prior studies.
- For ALTO-300 (adjunctive depression treatment), the Phase IIB study was upsizing after a positive interim analysis, with enrollment completion projected for mid-next year.
- To improve data quality and mitigate risks, Alto Neuroscience is implementing higher rigor in its clinical trials, including requiring medical/pharmacy records and blood/urine samples to confirm drug adherence.
Sep 17, 2025, 5:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more